Novartis Tops Q1 EPS by 2c
- ByInvesting.com-
Novartis (NYSE:NVS) reported Q1 EPS of $1.46, $0.02 better than the analyst estimate of $1.44. Revenue for the quarter came in at $12.53 billion versus the consensus estimate of...
Novartis (NYSE:NVS) reported Q1 EPS of $1.46, $0.02 better than the analyst estimate of $1.44. Revenue for the quarter came in at $12.53 billion versus the consensus estimate of...
Investing.com - Novartis ADR reported on Tuesday first quarter earnings that beat analysts' forecasts and revenue that fell short of expectations. Novartis ADR announced earnings...
(Reuters) – Core operating income at Novartis edged 3% higher in the first quarter as sales growth from new drugs was partly offset by unfavourable currency effects.
Concerns over high inflation levels and the war in Ukraine have meant increased volatility for stocks on Wall Street and other exchanges around the world. For instance, the DAX...
Interest rates in the US are going up. The country's red-hot inflation level has prompted the Federal Reserve to step in to achieve its dual mandate of "price stability and maximum...
Executive SummaryShareholder meetings and conferences ramp up after a busy summer and ahead of the next earnings seasonThe Delta variant forced many companies to quickly switch...
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
| Summary | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 102.26 | 102.40 | 99.38 | +3.51 | +3.55% | 103.91M | NASDAQ | |||
| 48.30 | 48.37 | 42.01 | +6.37 | +15.19% | 31.52M | NASDAQ | |||
| 19.93 | 20.02 | 19.58 | +0.24 | +1.22% | 281.27K | NYSE | |||
| 171.77 | 171.81 | 170.20 | +1.66 | +0.98% | 6.71M | NASDAQ | |||
| 91.04 | 91.05 | 89.84 | +1.28 | +1.43% | 1.76M | NYSE | |||
| 78.76 | 78.78 | 76.99 | +1.75 | +2.27% | 4.72M | NYSE | |||
| 177.97 | 178.35 | 175.52 | +3.84 | +2.21% | 5.80M | NASDAQ | |||
| 13.68 | 14.71 | 10.25 | +4.040 | +41.91% | 100.69M | NASDAQ | |||
| 89.73 | 90.36 | 87.65 | +1.10 | +1.24% | 406.46K | NYSE | |||
| 8.24 | 8.28 | 8.22 | -0.20 | -2.32% | 1.95K | OTC Markets | |||
| 160.00 | 162.64 | 150.22 | +17.87 | +12.57% | 6.73M | NASDAQ | |||
| 43.71 | 43.75 | 42.95 | +0.67 | +1.56% | 4.92M | NASDAQ | |||
| 507.11 | 507.11 | 489.39 | +4.88 | +0.97% | 3.34M | NYSE | |||
| 82.98 | 82.98 | 81.29 | +1.45 | +1.78% | 440.85K | NYSE | |||
| 96.71 | 96.72 | 95.20 | +1.71 | +1.80% | 3.38M | NYSE |